News & Trends - Pharmaceuticals

First dual immunotherapy regimen reimbursed for lung cancer

Health Industry Hub | March 31, 2021 |
[Total: 1    Average: 5/5]

Pharma News: Bristol-Myers Squibb (BMS) welcomed the listing on the Pharmaceutical Benefits Scheme (PBS) of OPDIVO (nivolumab) in combination with YERVOY (ipilimumab) with two cycles of platinum-doublet chemotherapy for the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC).

This innovative regimen is built on the only approved dual immunotherapy foundation. The combination of Opdivo plus Yervoy has previously demonstrated long-term survival outcomes across melanoma and renal cell carcinoma.

This listing is the first-ever for dual immunotherapy plus 2 cycles of chemotherapy for the treatment of NSCLC. NSCLC accounts for around 85% of lung cancer cases.

Associate Professor Tom John, Medical Oncologist at the Peter MacCallum Cancer Centre, welcomed the announcement that will make new first-line treatments available to Australian patients who are affected by the squamous form of NSCLC.

“New evidence-based treatment options that are reimbursed are very welcome because lung cancer has historically been associated with low survival expectations for patients diagnosed at an advanced stage,” said Associate Professor John.

Digital & Innovation - Health Industry Hub Digital Series

According to Associate Professor John, the reimbursement of new combinations of medicines in first-line lung cancer is crucial to improving patient outcomes.

“New listings give clinicians additional options to consider and trigger new conversations to have with our patients. Listings like this are important given the clinical evidence behind them,” added Associate Professor John.

Dr Melinda Munns, Medical Director for BMS Australia and New Zealand said this listing was positive news for suitable patients who would benefit from improved access to dual immunotherapy with chemotherapy treatment in the first-line NSCLC setting.

“This reimbursement is all about providing new, accessible and effective options for patients who have the squamous form of non-small cell lung cancer. It demonstrates the commitment of BMS to provide new first-line treatments for metastatic lung cancer patients,” said Dr Munns.

“As ever, BMS is committed to pursuing innovative approaches to lung cancer treatment so we can continue to deliver the right medicine, to the right patient, at the right time. We look forward to working with the PBAC on making OPDIVO (nivolumab) plus YERVOY (ipilimumab) with two cycles of platinum-doublet chemotherapy a first-line option for non-squamous, stage IV non-small cell lung cancer patients.”

The PBS listing was based on results from the randomised phase III clinical trial, CheckMate -9LA, which provides important evidence for the clinical benefit of OPDIVO (nivolumab) plus YERVOY (ipilimumab) with two cycles of platinum-doublet chemotherapy vs chemotherapy alone. CheckMate -9LA study results showed a statistically significant improvement in overall survival for previously untreated recurrent/metastatic NSCLC patients treated with OPDIVO, YERVOY and platinum-doublet chemotherapy compared to platinum-doublet chemotherapy alone at a prespecified
interim analysis (at a minimum follow-up of 8.1 months, [HR 0.69; 96.71% CI: 0.55, 0.87; p=0.0006]).

Additionally, with longer follow-up (minimum of 12.7 months), dual immunotherapy with two cycles of chemotherapy continued to show sustained OS improvements over chemotherapy alone (median OS of 15.6 months versus 10.9 months, respectively [HR: 0.66, 95% CI: 0.55 to 0.80]).

You may also like First IL-17A inhibitor PBS listed for non-radiographic axial spondyloarthritis

About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Leadership & Management

Leadership Management Qualities - The power of being an authentic leader

The power of being an authentic leader

Health Industry Hub | April 21, 2021 |

Leadership & Management: Welcome to Health Industry Hub’s Women in Leadership Series – connecting, engaging and empowering women in the […]


Digital & Innovation

Healthcare Technology Digital Innovations - Data is the biggest challenge, and opportunity, for MedTech

Data is the biggest challenge, and opportunity, for MedTech

Health Industry Hub | April 21, 2021 |

Digital & Innovation: Medical technology is increasingly shaping the future of healthcare. The sector is also a growing part of […]


News & Trends - Medical Technology

MedTech News - Thermo Fisher acquisition to better serve its pharma and biotech clients

Thermo Fisher acquisition to better serve its pharma and biotech clients

Health Industry Hub | April 21, 2021 |

MedTech News: Thermo Fisher Scientific is buying clinical research services provider PPD for a hearty $17.4 billion, and that’s not its only acquisition this […]


News & Trends - Pharmaceuticals

Pharma News - First-in-class oncology drug candidate licensed by Aussie pharma

First-in-class oncology drug candidate licensed by Aussie pharma

Health Industry Hub | April 21, 2021 |

Pharma News: An Australian oncology-focused drug development company entered into a worldwide exclusive licensing agreement and a master services agreement […]